TY - JOUR
T1 - Orally active-targeted drug delivery systems for proteins and peptides
AU - Li, Xiuying
AU - Yu, Miaorong
AU - Fan, Weiwei
AU - Gan, Yong
AU - Hovgaard, Lars
AU - Yang, Mingshi
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Introduction: In the past decade, extensive efforts have been devoted to designing 'active targeted' drug delivery systems (ATDDS) to improve oral absorption of proteins and peptides. Such ATDDS enhance cellular internalization and permeability of proteins and peptides via molecular recognition processes such as ligand-receptor or antigen-antibody interaction, and thus enhance drug absorption.Areas covered: This review focuses on recent advances with orally ATDDS, including ligand-protein conjugates, recombinant ligand-protein fusion proteins and ligand-modified carriers. In addition to traditional intestinal active transport systems of substrates and their corresponding receptors, transporters and carriers, new targets such as intercellular adhesion molecule-1 and β-integrin are also discussed.Expert opinion: ATDDS can improve oral absorption of proteins and peptides. However, currently, no clinical studies on ATDDS for proteins and peptides are underway, perhaps due to the complexity and limited knowledge of transport mechanisms. Therefore, more research is warranted to optimize ATDDS efficiency.
AB - Introduction: In the past decade, extensive efforts have been devoted to designing 'active targeted' drug delivery systems (ATDDS) to improve oral absorption of proteins and peptides. Such ATDDS enhance cellular internalization and permeability of proteins and peptides via molecular recognition processes such as ligand-receptor or antigen-antibody interaction, and thus enhance drug absorption.Areas covered: This review focuses on recent advances with orally ATDDS, including ligand-protein conjugates, recombinant ligand-protein fusion proteins and ligand-modified carriers. In addition to traditional intestinal active transport systems of substrates and their corresponding receptors, transporters and carriers, new targets such as intercellular adhesion molecule-1 and β-integrin are also discussed.Expert opinion: ATDDS can improve oral absorption of proteins and peptides. However, currently, no clinical studies on ATDDS for proteins and peptides are underway, perhaps due to the complexity and limited knowledge of transport mechanisms. Therefore, more research is warranted to optimize ATDDS efficiency.
KW - Active-targeted drug delivery systems
KW - IgG-Fc receptor
KW - Intercellular adhesion molecule-1
KW - Oral protein and peptide delivery
KW - Proton-coupled folate transporter
KW - Recombinant fusion protein
KW - Transferrin receptor
UR - http://www.scopus.com/inward/record.url?scp=84906316137&partnerID=8YFLogxK
U2 - 10.1517/17425247.2014.924500
DO - 10.1517/17425247.2014.924500
M3 - Review
C2 - 24962803
AN - SCOPUS:84906316137
SN - 1742-5247
VL - 11
SP - 1435
EP - 1447
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 9
ER -